Clinical Trial Update: FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC [Phase 2, Phase 3]

View source ↗

Summary

FORTIFI-HN01 is a Phase 2/3 trial evaluating Ficerafusp Alfa (BCA101) with pembrolizumab versus placebo with pembrolizumab in first-line PD-L1-positive metastat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Ficerafusp Alfa (ficerafusp alfa)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Bicara Therapeutics | Conditions: Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2, Phase 3 | Status: RECRUITING